Within the microenvironment, targeted blockade of vascular endothelial growth factor (VEGF), such as bevacizumab, signaling to interrupt angiogenesis and deplete the tumor nutrient supply has shown promise in vitro and has led to FDA approval in several cancer types (Sasich and Sukkari, 2012). The gene discussed is VEGFA; the disease is cancer.